GEN 1055
Alternative Names: BNT-315; GEN-1055; HexaBody-OX40Latest Information Update: 17 May 2024
At a glance
- Originator Genmab
- Developer BioNTech; Genmab
- Class Antibodies; Antineoplastics; Immunotherapies
- Mechanism of Action OX40 ligand modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 30 Apr 2024 Phase-I/II clinical trials in Solid tumours (Combination therapy, Late-stage disease, Second-line therapy or greater, Metastatic disease) in Spain (IV) (NCT06391775)
- 30 Apr 2024 Phase-I/II clinical trials in Solid tumours (Second-line therapy or greater, Late-stage disease, Metastatic disease, Monotherapy) in Spain (IV) (NCT06391775)